Shockwave Intravascular Lithotripsy is a novel procedure that brings hope for those suffering from an advanced form of coronary artery disease (CAD) having angina or heart attack in which the blockage becomes very hard due to deposit of calcium. This happens in 20 per cent - 25 per cent of the patients especially those who are elderly, diabetic have chronic kidney disease, have long-standing blockages or previous bypass surgery.
Previously to tackle this heavily calcified blockage there were only drills called Rotablator or ultra-high pressure balloons which are difficult to use and carry the risk of rupturing the artery.
Shockwave Intravascular Lithotripsy (IVL) system, mechanism of action and procedural overview
Intravascular Lithotripsy launched by Shockwave Medical, USA is an innovative technology that generates sonic pressure waves to break up problematic calcium so that the artery can be opened with ease and blood flow restored with the placement of a stent. The therapy leverages a similar minimally invasive approach that has been embraced by physicians for decades to treat kidney stones, which are also made up of calcium.
"We are happy to be the first to offer this innovative technology to the benefit of the numerous patients in India undergoing angioplasties", said Dr Ashok Seth, Chairman, Fortis Escorts Heart Institute, New Delhi after he and his team performed the first case in the country.
"Hardened calcified blockages are a big challenge to treat by angioplasty and stents and is getting commoner. Such blockages can now be opened with ease and safety to give patients the best results for the long term. The sonic pressure waves produced when performing Intravascular Lithotripsy gives us a novel, safe and proven treatment option to break up the calcified plaque, with potentially less risk of injury to the artery compared to other treatments", he added.
Dr Jonathan Hill, Head of Department of Cardiology, King's College Hospital, London, who has the highest experience with this therapy in the world, was present with Dr Seth during the first case.
"This is a path-breaking therapy which is revolutionizing the treatment of hard plaque in Coronary arteries world over and I am glad that this is now available in India to patients in India. This will bring hope for many patients whose arteries could not be opened by balloon angioplasty because of calcium build-up and were considered for Bypass Surgeries or left on medical management", said Dr Jonathan Hill.
Calcium slowly develops and progresses to its hardened, bone-like state over the course of several decades of cellular growth and death in diseased plaque within the heart arteries. While it is slow to develop, its impact is immediately encountered when performing procedures in calcified lesions.
The calcium's hardened structure restricts normal artery movement and makes the rigid arterial tissue resistant to traditional balloon therapies that have been designed to compress the plaque within the artery wall to restore normal blood flow. For these reasons, the presence of calcium increases the complexity of most cases and decreases the effectiveness of most treatments.
"Indian is amongst the ten countries where this therapy has been launched and we are happy that Indian patients now may not need to travel abroad to get IVL", said Gurmit Singh Chugh, CEO, Translumina, partners of Shockwave Medical for India.
How Intravascular Lithotripsy (IVL) works
Intravascular Lithotripsy uses a small generator to produce therapeutic sonic pressure waves from a catheter that is threaded through the arterial system to the site of the blockage.
The pressure waves pass through the soft vascular tissue, preferentially disrupting the hardened calcified plaque inside the arterial wall by creating a series of micro-fractures.
After the calcium has been modified, the artery can be expanded using a low-pressure balloon and a stent, thereby enabling even historically challenging CAD patients to be treated effectively with minimal injury to the vessel.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. It aims to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which Shockwave Medical refers to as Intravascular Lithotripsy.
IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.
Translumina is a leading global manufacturer and distributor of cardiac stents and cardiovascular medical devices. Translumina Therapeutics was founded by Gurmit Singh Chugh and Punita Sharma Arora with an objective to create path-breaking technologies for providing better healthcare solutions to the physicians & patients for improving clinical outcomes for various cardiac disorders.
Translumina's technologies are developed in collaboration with the German Heart Centre and are endorsed by the European Society of Cardiology.
Translumina combines the best of German technology, intellectual property and high-quality standards with Indian capabilities of manufacturing innovative products at affordable prices.
This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)